Sonoma Pharmaceuticals Price to Free Cash Flow Ratio 2010-2025 | SNOA

Sonoma Pharmaceuticals price to free cash flow ratio from 2010 to 2025. Price to free cash flow ratio can be defined as

Sonoma Pharmaceuticals Price to Free Cash Flow Ratio 2010-2025 | SNOA

Sonoma Pharmaceuticals price to free cash flow ratio from 2010 to 2025. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$69.6B
Zoetis (ZTS)$69B
Takeda Pharmaceutical (TAK)$48.7B
Daiichi Sankyo, - (DSNKY)$47.9B
BeOne Medicines - (ONC)$34.4B
Sandoz Group AG (SDZNY)$26.7B
Summit Therapeutics (SMMT)$19.3B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.9B
United Therapeutics (UTHR)$14B
Neurocrine Biosciences (NBIX)$13.4B
IPSEN (IPSEY)$11.3B
Orion OYJ (ORINY)$11.2B
Eisai (ESAIY)$9.1B
Madrigal Pharmaceuticals (MDGL)$9B
Corcept Therapeutics (CORT)$7.5B
Grifols, S.A (GRFS)$6.9B
Stevanato Group S.p.A (STVN)$6.9B
Ionis Pharmaceuticals (IONS)$6.9B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.7B
Procaps Group, S.A (PROCF)$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.8B
NewAmsterdam Pharma (NAMS)$2.8B
Hypermarcas (HYPMY)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B